Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

SELL
$74.43 - $92.22 $56,566 - $70,087
-760 Reduced 4.36%
16,678 $1.37 Million
Q1 2024

Apr 17, 2024

SELL
$83.81 - $99.0 $2,933 - $3,465
-35 Reduced 0.2%
17,438 $1.52 Million
Q4 2023

Jan 19, 2024

BUY
$76.22 - $98.51 $34,527 - $44,625
453 Added 2.66%
17,473 $1.68 Million
Q2 2023

Aug 01, 2023

BUY
$86.68 - $100.3 $188,529 - $218,152
2,175 Added 14.65%
17,020 $1.48 Million
Q1 2023

May 09, 2023

SELL
$87.74 - $117.27 $9,739 - $13,016
-111 Reduced 0.74%
14,845 $1.44 Million
Q4 2022

Jan 20, 2023

BUY
$80.93 - $108.63 $1.21 Million - $1.62 Million
14,956 New
14,956 $0
Q2 2022

Jul 19, 2022

SELL
$71.48 - $86.85 $331,667 - $402,984
-4,640 Closed
0 $0
Q1 2022

Apr 12, 2022

SELL
$74.28 - $92.69 $544,472 - $679,417
-7,330 Reduced 61.24%
4,640 $358,000
Q4 2021

Jan 28, 2022

BUY
$71.72 - $91.47 $38,728 - $49,393
540 Added 4.72%
11,970 $1.06 Million
Q3 2021

Nov 05, 2021

SELL
$74.77 - $85.47 $36,263 - $41,452
-485 Reduced 4.07%
11,430 $883,000
Q2 2021

Jul 28, 2021

SELL
$75.51 - $84.79 $131,009 - $147,110
-1,735 Reduced 12.71%
11,915 $994,000
Q1 2021

May 04, 2021

BUY
$74.73 - $90.69 $176,736 - $214,481
2,365 Added 20.96%
13,650 $1.03 Million
Q4 2020

Jan 27, 2021

BUY
$72.61 - $90.2 $15,248 - $18,942
210 Added 1.9%
11,285 $990,000
Q3 2020

Nov 12, 2020

BUY
$71.87 - $131.03 $21,920 - $39,964
305 Added 2.83%
11,075 $843,000
Q2 2020

Aug 18, 2020

SELL
$79.55 - $124.22 $5,966 - $9,316
-75 Reduced 0.69%
10,770 $1.33 Million
Q1 2020

May 18, 2020

BUY
$71.37 - $96.85 $774,007 - $1.05 Million
10,845 New
10,845 $916,000
Q3 2019

Nov 05, 2019

SELL
$67.4 - $85.11 $15,839 - $20,000
-235 Closed
0 $0
Q2 2019

Aug 19, 2019

BUY
$80.35 - $93.9 $18,882 - $22,066
235 New
235 $20,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Griffin Asset Management, Inc. Portfolio

Follow Griffin Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Griffin Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Griffin Asset Management, Inc. with notifications on news.